Karil Bellah, MD
Cardiovascular Disease · Salina, KSNPI 1518921485
Payments from drug & device makers
Across 426 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Medtronic$868
- Merck$735
- Johnson & Johnson$675
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$549
- Amgen$535
- plus $2K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 84 | $1,028 |
| Medtronic(2 entities) | 59 | $868 |
| Merck | 47 | $735 |
| Johnson & Johnson | 46 | $675 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $549 |
| Amgen | 31 | $535 |
| AstraZeneca | 29 | $449 |
| Pfizer | 19 | $275 |
| Amarin Pharma, Inc. | 10 | $206 |
| Abbott | 3 | $167 |
| Bayer | 2 | $166 |
| Boehringer Ingelheim | 9 | $165 |
| E.r. Squibb & Sons, L.L.C. | 7 | $105 |
| Regeneron Healthcare Solutions, Inc. | 5 | $96 |
| Astellas Pharma US Inc | 3 | $66 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Bardy Diagnostics, Inc. | 3 | $57 |
| Kestra Medical Technology Services, Inc. | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $56 |
| Philips North America LLC | 2 | $51 |
| Boston Scientific | 3 | $51 |
| Abiomed | 2 | $49 |
| Gilead | 3 | $44 |
| Akcea Therapeutics, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Amryt Pharma Holdings Ltd | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Infobionic, Inc | 1 | $17 |
| Cvrx, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| EKOS Corporation | 1 | $14 |
| Bracco Diagnostics Inc. | 1 | $13 |
How this compares
$6,744 in reported general payments places this provider in the 70th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Salina
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Stephen BloomOverland Park$766K
- Vasvi SinghOverland Park$436K
- Lloyd StahlOverland Park$275K
- Thomas AshcomWichita$193K
- Chen Hoe ChowTopeka$187K
- Joseph GalichiaWichita$177K
- Mazhar AfaqKansas City$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.